Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Staar Surgical in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Staar Surgical’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000718937-26-000023
| Line item | Three Months Ended / April 3, 2026 | Three Months Ended / March 28, 2025 |
|---|---|---|
| Selling, general and administrative expenses: | ||
| General and administrative | 17,022 | 24,458 |
| Selling and marketing | 24,509 | 26,945 |
| Research and development | 9,925 | 11,339 |
| Merger transaction and related costs | 6,743 | — |
| Restructuring, impairment and related charges | 2,681 | 22,664 |
| Total selling, general and administrative expenses | 60,880 | 85,406 |
| Operating income (loss) | 7,979 | (57,401) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Staar Surgical's R&D?
- Staar Surgical (STAA) reported R&D of $9.93M in Q1 2026.
- How has Staar Surgical's R&D changed year-over-year?
- Staar Surgical's R&D decreased by 12.5% year-over-year, from $11.34M to $9.93M.
- What is the long-term trend for Staar Surgical's R&D?
- Over 4 years (2021 to 2025), Staar Surgical's R&D has grown at a 4.3% compound annual growth rate (CAGR), from $33.86M to $40.06M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Staar Surgical's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude